Cor Vasa 2002, 43(1):38-42

Atrial fibrillation: current potential for treatment or (old) new guidelines

Robert Čihák
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika

Atrial fibrillation (AF) is an arrhythmia with increasing prevalence. Management is individualized depending on the severity and frequency of problems and presence of heart disease. The mainstay of therapy is prevention of thromboembolic events using anticoagulation or antiaggregation therapy, depending on risk stratification in a specific patient. A similar technique of prevention should be used for atrial flutter. It is not clear at the moment whether it is better-in terms of morbidity and mortality-to make every effort to maintain sinus rhythm with antiarrhythmics or just to monitor heart rate and prevent thromboemobolic events. Should pharmacotherapy fail, non-pharmacological (palliative or curative) therapy is instituted. The potential of catheter ablation (pulmonary artery isolation in particular) has improved dramatically. Hybrid therapy, as a combination of several procedures, has been shown to be effective in many patients.

Keywords: Atrial fibrillation; Prevention of thromboembolic events; Antiarrhythmics; Hybrid therapy; Catheter ablation

Published: January 1, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čihák R. Atrial fibrillation: current potential for treatment or (old) new guidelines. Cor Vasa. 2002;43(1):38-42.
Download citation




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.